[Therapy with interleukin 2 for chronic viral hepatitis].
We administered 250-10,000 u of recombinant interleukin 2 (r-IL2) for 1-4 weeks intravenously or intramuscularly to patients with chronic hepatitis B positive for serum HBe antigen as immunostimulants and studied the effect of r-IL2 for antiviral system. Serum ALT levels increased during the therapy and then decreased after the treatment. Activities of DNA-P were gradually reduced and became negative in 6 of 11 cases. Serum HBeAg decreased and anti-HBe increased during and after the therapy. Peripheral lymphocytes and eosinocytes increased during the therapy but returned to the pretreatment level after the therapy. TSI (%) increased rapidly and TS (%) decreased during infusion of r-IL2. However, TH/TS ratio increased after the infusion since TH (%) decreased gradually during the infusion of r-IL2. The r-IL2 therapy was useful for chronic hepatitis with serum HBe antigen as therapy with immunostimulant or treatment with biological response modifier (BRM).
Kuroki
T
T
Third Department of Internal Medicine, Osaka City University Medical School.
D002908:Chronic Disease; D006509:Hepatitis B / Q000628:therapy*; D007376:Interleukin-2 / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins